Peptide Composition for IL-4 and IL-13 Control in Asthma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bronchial allergic diseases, such as asthma, have significant side effects and fail to effectively control symptoms, while existing drugs increase the risk of death and do not address the underlying immune imbalance.
Innovation Solution
A peptide composition containing polypeptides with IL-4 and IL-13 inhibitory activity, administered to individuals, regulates immune responses and reduces cytokine levels, thereby alleviating bronchial allergic symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral steroids are used for long-term asthma treatment, then asthma symptoms are controlled, but side effects such as osteoporosis and moon face occur
Solution Approach 1:
The patent extracts and targets specific harmful cytokines (IL-4 and IL-13) that mediate asthma pathology, separating the therapeutic action from non-specific immunosuppression. By selectively inhibiting these specific cytokines rather than using broad-spectrum steroids, the patent achieves asthma control while avoiding the harmful side effects of systemic immunosuppression.
Solution Approach 2:
The patent changes the molecular target parameter from non-specific immune suppression to specific cytokine inhibition. By focusing on IL-4 and IL-13 pathways, the treatment modifies the immunological parameter profile to achieve asthma control through targeted mechanism rather than broad suppression, thereby eliminating steroid-related side effects.
2Ease of operation
If bronchodilators are used for daily asthma control, then breathing difficulty is relieved temporarily, but asthma symptoms persist and death risk increases
Solution Approach 1:
The patent applies preliminary action by preventing the underlying immune imbalance before asthma symptoms manifest. By continuously inhibiting IL-4 and IL-13 production, the treatment prevents airway inflammation and hyperresponsiveness from developing, rather than merely providing temporary relief during attacks. This proactive approach eliminates the need for daily bronchodilator use.
Solution Approach 2:
The patent converts the harmful chronic inflammation that sustains asthma into a beneficial controlled state. By targeting and inhibiting the inflammatory cytokines IL-4 and IL-13, the treatment transforms the harmful immune response into a controlled state, eliminating asthma symptoms without requiring continuous bronchodilator intervention.
3Reliability
If multiple medications are used to control asthma symptoms, then bronchial allergy is managed, but drug dependency increases and underlying immune imbalance remains unaddressed
Solution Approach 1:
The patent extracts the root cause of asthma symptoms by targeting the specific cytokines IL-4 and IL-13 that drive the immune imbalance. By removing this underlying cause through targeted inhibition, the treatment eliminates the need for multiple symptomatic medications, simplifying the overall treatment approach while maintaining reliable symptom control.
Solution Approach 2:
The patent achieves multi-functionality by using a single targeted mechanism (IL-4 and IL-13 inhibition) that simultaneously addresses multiple aspects of asthma pathology including inflammation, airway hyperresponsiveness, and mucus production. This unified approach replaces the need for multiple specialized medications, reducing drug regimen complexity while maintaining comprehensive symptom control.
Data Source
AI summary
A method for treating or preventing a bronchial allergic disease with a peptide composition includes administering an effective amount of the peptide composition to an individual in need of the peptide composition so as to improve or prevent asthma or another bronchial allergic disease. The peptide composition has at least one polypeptide, and the amino acid sequence of the polypeptide is represented by one of SEQ ID No. 1 to SEQ ID No. 10.